© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Delcath Systems, Inc. (DCTH) stock surged +2.04%, trading at $11.02 on NASDAQ, up from the previous close of $10.80. The stock opened at $10.75, fluctuating between $10.75 and $11.28 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 04, 2026 | 10.75 | 11.28 | 10.75 | 11.02 | 387.06K |
| Apr 30, 2026 | 10.24 | 10.53 | 10.14 | 10.38 | 293.6K |
| Apr 29, 2026 | 10.43 | 10.44 | 10.05 | 10.21 | 263.98K |
| Apr 28, 2026 | 10.75 | 10.87 | 10.53 | 10.55 | 191.93K |
| Apr 27, 2026 | 10.82 | 11.10 | 10.81 | 10.84 | 231.88K |
| Apr 23, 2026 | 11.20 | 11.20 | 10.58 | 10.64 | 304.95K |
| Apr 22, 2026 | 10.77 | 11.20 | 10.68 | 11.19 | 331.26K |
| Apr 21, 2026 | 10.92 | 10.95 | 10.61 | 10.66 | 275.62K |
| Apr 20, 2026 | 10.72 | 11.04 | 10.61 | 10.88 | 342.09K |
| Apr 17, 2026 | 11.05 | 11.05 | 10.80 | 10.86 | 316.4K |
| Apr 16, 2026 | 10.99 | 10.99 | 10.75 | 10.83 | 239.26K |
| Apr 14, 2026 | 10.50 | 10.92 | 10.46 | 10.88 | 304.09K |
| Apr 13, 2026 | 9.99 | 10.47 | 9.96 | 10.45 | 359.09K |
| Apr 10, 2026 | 9.90 | 10.14 | 9.85 | 10.04 | 322.55K |
| Apr 09, 2026 | 9.75 | 9.97 | 9.70 | 9.88 | 180.38K |
| Apr 08, 2026 | 10.00 | 10.05 | 9.76 | 9.85 | 306.72K |
| Apr 07, 2026 | 9.65 | 9.79 | 9.53 | 9.67 | 234K |
| Apr 06, 2026 | 9.67 | 9.88 | 9.47 | 9.70 | 222.59K |
| Apr 02, 2026 | 9.34 | 9.65 | 9.29 | 9.63 | 286.54K |
| Apr 01, 2026 | 9.40 | 9.63 | 9.35 | 9.54 | 304.61K |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
| Employees | 96 |
| Beta | 0.43 |
| Sales or Revenue | $2.07M |
| 5Y Sales Change% | -0.999% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |